Related Experiment Video
Updated: Aug 6, 2026
04:33
Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder
Published on: April 26, 2024
Identification of AICD-associated transcriptomic markers in major depressive disorder
Shengjie Xiong1, Lixin Liao1, Meng Chen2
1Department of Psychiatry, West China School of Medicine, Sichuan University, Sichuan University Affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, Chengdu, Sichuan, China.
Frontiers in Psychiatry
|July 23, 2026
Summary
Researchers identified MRPL53 and RPL24 as key genes linked to ATP-induced cell death in Major Depressive Disorder (MDD). These findings offer new insights into MDD pathogenesis and suggest hydralazine as a potential therapeutic target.
Area of Science:
- Genomics
- Neuroscience
- Molecular Biology
Background:
- Major Depressive Disorder (MDD) pathogenesis remains incompletely understood at the molecular level.
- Identifying key genes involved in ATP-induced cell death (AICD) is crucial for understanding MDD.
- This study focuses on elucidating the role of specific genes in MDD development.
Purpose of the Study:
- To identify key genes associated with AICD in MDD.
- To explore the role of these genes in MDD pathogenesis.
- To investigate potential therapeutic strategies targeting these genes.
Main Methods:
- Analysis of MDD transcriptome data from public databases.
- Differential gene expression analysis, Weighted Gene Co-expression Network Analysis (WGCNA), and machine learning.
- Construction and validation of a diagnostic nomogram, functional enrichment, immune infiltration, and molecular docking analyses.
Main Results:
- MRPL53 and RPL24 identified as key diagnostic genes for MDD (AUC > 0.7).
- A nomogram incorporating these genes showed high diagnostic accuracy (AUC = 0.967).
- Significant pathway enrichments (ribosome, neuroactive ligand-receptor interaction, oxidative phosphorylation) and altered immune microenvironment observed; hydralazine identified as a potential therapeutic candidate via molecular docking.
Conclusions:
- MRPL53 and RPL24 are potential AICD-associated transcriptomic markers in MDD.
- These genes provide novel insights into MDD pathogenesis.
- Hydralazine is a potential therapeutic candidate, requiring further validation.
